AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

AbbVie (ABBV) is acquiring clinical-stage biotech Apogee Therapeutics for $10.9 billion in cash, paying $135.11 per share. The deal targets Apogee's immunology pipeline, anchored by zumilokibart, a candidate in development for eczema and asthma.

The acquisition bolsters AbbVie's immunology franchise as it manages the ongoing erosion of Humira revenues following biosimilar competition. Zumilokibart and other Apogee assets are designed to extend AbbVie's reach in dermatology and respiratory indications beyond its current portfolio.

Analysts project near-term earnings per share dilution from the deal, with accretion not expected until 2032. AbbVie maintains a dividend yield above 3% and holds Dividend King status, having raised its payout for 25 consecutive years. The $135.11 per share price represents a significant premium to Apogee's pre-announcement trading levels, typical for acquisitions of pre-revenue biotech assets with clinical promise.

The transaction adds late-stage pipeline depth but pushes meaningful earnings contributions nearly a decade out, creating a tension between immediate financial drag and long-term strategic positioning.